- Home
- ADEA vs LGND Comparison
ADEA vs LGND Comparison
Compare ADEA & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADEA | LGND |
|---|---|---|
| Founded | 1990 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ADEA | LGND |
|---|---|---|
| Price | $32.62 | $254.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $31.00 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 2.3M | 156.4K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | ★ 73.68 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $443,386,000.00 | N/A |
| Revenue This Year | N/A | $1.25 |
| Revenue Next Year | $5.63 | $19.41 |
| P/E Ratio | $154.25 | ★ $76.27 |
| Revenue Growth | ★ 17.91 | N/A |
| 52 Week Low | $11.61 | $111.72 |
| 52 Week High | $34.34 | $257.19 |
Technical Indicators
Market Signals| Indicator | ADEA | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 56.45 | 74.17 |
| Support Level | $26.33 | $199.97 |
| Resistance Level | $34.34 | N/A |
| Average True Range (ATR) | 2.43 | 7.26 |
| MACD | 0.24 | 2.33 |
| Stochastic Oscillator | 71.93 | 96.51 |
Price Performance
Historical ComparisonAbout ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. It's the only operating segment, being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.